Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, rAndomized, Double-blind, Placebo-conTrolled, 52-week stUdy to demonstRatE the Efficacy, Safety and Tolerability of Secukinumab Injections With 2 mL Auto-injectors (300 mg) in Adult Subjects With Plaque Psoriasis
Brief Summary: The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis


Options:
A: Arm Label: Placebo 2 mL auto-injector; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo 2 mL auto-injector | Arm Label: Placebo 1 mL prefilled syringe; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo 1 mL prefilled syringe | Arm Label: Secukinumab 2 mL auto-injector; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL auto-injector | Arm Label: Secukinumab 1 mL prefilled syringe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL prefilled syringe | Intervention Type: DRUG; Name: Placebo 2 mL auto-injector; Assigned to Arm(s): Placebo 2 mL auto-injector | Intervention Type: DRUG; Name: Placebo 1 mL prefilled syringe; Assigned to Arm(s): Placebo 1 mL prefilled syringe | Intervention Type: DRUG; Name: Secukinumab 2 mL auto-injector; Assigned to Arm(s): Secukinumab 2 mL auto-injector | Intervention Type: DRUG; Name: Secukinumab 1 mL prefilled syringe; Assigned to Arm(s): Secukinumab 1 mL prefilled syringe
B: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW
C: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)
D: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C

Answer: A